<DOC>
	<DOCNO>NCT01440179</DOCNO>
	<brief_summary>Primary Objective : Participants achieve Objective Response Rate Secondary Objectives : - Response duration - Progression Free Survival - Minimal residual disease - Safety - Pharmacokinetics</brief_summary>
	<brief_title>SAR3419 Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The duration study individual patient include : - The screening period = 4 week prior first administration SAR3419 . - The treatment period : - Induction period = 4 8 week - Maintenance = total maintenance treatment 6 month - A safety follow-up period 42 day last dose . - Any patient discontinues study treatment without disease progression follow every 2 month disease progression , initiation new anti-cancer therapy , death end-of-study date , whatever come first .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Inclusion criterion : Previously treat Acute Lymphoblastic Leukemia B cell origin ( include Burkitt 's lymphoma ) relapse primary refractory . Patients first relapse eligible regardless first remission duration . No 3 prior salvage therapy . Philadelphia positive patient fail treatment imatinib mesylate accept . CD19 positive patient . Exclusion criterion : The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>